-
公开(公告)号：US20240327505A1
公开(公告)日：2024-10-03
申请号：US18703646
申请日：2022-10-20
CPC分类号： C07K16/1003 , A61P31/14 , A61K2039/505 , C07K2317/565 , C07K2317/76
摘要： Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.
-
公开(公告)号：US20240301037A1
公开(公告)日：2024-09-12
申请号：US18272030
申请日：2022-01-24
CPC分类号： C07K16/1003 , A61P37/04 , A61K2039/505 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods are disclosed for treating and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus spike protein or mutants thereof.
-
公开(公告)号：US20240287162A1
公开(公告)日：2024-08-29
申请号：US18589364
申请日：2024-02-27
发明人： Nianshuang WANG , Yang SHEN , Alina BAUM , Christos KYRATSOUS , Chia-Yang LIN , Tri NGUYEN
CPC分类号： C07K16/1003 , A61P31/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/35
摘要： The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
-
公开(公告)号：US20240262892A1
公开(公告)日：2024-08-08
申请号：US18245154
申请日：2021-09-14
发明人： Lin CAO , Bai LU , Yang DOU , Jianfeng PAN , Lingjie XU , Xiaoyu XU
CPC分类号： C07K16/1003 , A61K2039/505 , C07K2317/76 , C07K2317/92
摘要： Provided are novel neutralizing antibodies against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
-
公开(公告)号：US20240254203A1
公开(公告)日：2024-08-01
申请号：US18560621
申请日：2022-05-19
发明人： Michael CHEN , Chang-Zheng CHEN , Yiling LUO , Hua ZHOU
IPC分类号： C07K16/10 , A61P31/14 , C07K14/005
CPC分类号： C07K16/1003 , A61P31/14 , C07K14/005 , C07K16/1018 , C07K2317/31 , C07K2317/35 , C07K2317/622 , C07K2319/02 , C07K2319/73 , C12N2760/16122 , C12N2760/18422 , C12N2760/20222 , C12N2770/20021 , C12N2770/24122
摘要： Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus, wherein the fusion protein is expressed at a valency of at least about 10 copies on a surface of the antivirus, and wherein the antibody neutralizes the virus when expressed within the fusion protein on the surface of the antivirus but does not neutralize the virus when expressed as an isolated antibody. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-COV-2).
-
公开(公告)号：US20240251767A1
公开(公告)日：2024-08-01
申请号：US18289508
申请日：2022-05-05
申请人： Leveragen, Inc.
发明人： Weisheng Victor CHEN
IPC分类号： A01K67/0278 , C07K16/10 , C12N15/85
CPC分类号： A01K67/0278 , C07K16/1003 , C12N15/8509 , A01K2207/15 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/01 , C07K2317/10 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/569 , C07K2317/92 , C12N2015/8518
摘要： This document provides genetically modified animals (e.g., mice), humanized heavy chain antibodies, humanized nanobodies, and methods of making and using the same. For example, genetically engineered non-human animals (e.g., genetically engineered mice) that can be designed to produce heavy chain antibodies that can be used to generate a single domain antibody or nanobody are provided.
-
公开(公告)号：US20240238451A1
公开(公告)日：2024-07-18
申请号：US18561653
申请日：2022-05-26
CPC分类号： A61K49/0058 , A61K49/0045 , C07K7/06 , C07K16/1003 , G01N21/6428 , C07K2317/31 , C07K2317/569 , C07K2319/30 , C07K2319/60 , G01N2021/6439
摘要： Provided herein are fusion proteins comprising a single domain antibody (sdAb) (including, but not limited to, a nanobody) that binds selectively to a specific antigen, wherein a second polypeptide is inserted into the single domain antibody, generating an internal fusion. Also provided are methods of making and methods of using the fusion proteins disclosed herein.
-
公开(公告)号：US20240218057A1
公开(公告)日：2024-07-04
申请号：US18558066
申请日：2022-05-05
CPC分类号： C07K16/1003 , A61K47/6841 , C07K2317/24 , C07K2317/31 , C07K2317/35
摘要： This disclosure provides novel neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-COV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-COV-2 infections.
-
公开(公告)号：US20240166727A1
公开(公告)日：2024-05-23
申请号：US18551217
申请日：2022-03-21
IPC分类号： C07K16/10 , G01N33/569 , G01N33/58
CPC分类号： C07K16/1003 , G01N33/56983 , G01N33/58 , C07K2317/76
摘要： The invention concerns antigen specific proteins, in particular antibodies or fragments thereof, specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor, said antigen specific proteins having neutralizing activity for infection of SARS-COV2 virus and its derived variants.
-
公开(公告)号：US20240158477A1
公开(公告)日：2024-05-16
申请号：US17756772
申请日：2022-01-25
发明人： Xiang Li , Yi Xiong , Shin-Chen Hou , Chenguang Cai , Yanbin Guan
CPC分类号： C07K16/1003 , A61K45/06 , A61K47/6841 , A61P31/14 , A61K2039/505
摘要： A nanobody capable of specifically recognizing SARS-CoV-2 spike glycoprotein RBD is provided, and the nanobody comprises a CDR having an amino acid sequence selected from at least one of the following or at least 95% identical to the following: a CDR sequence of a heavy chain variable region: SEQ ID NO: 1˜21.
-
-
-
-
-
-
-
-
-
搜索结果
135 条记录 (耗时 0.03 秒)
